An experimental gene editing cell therapy for sickle cell disease has shown encouraging early results in a phase 1/phase 2 multicenter clinical trial, according to researchers at Cleveland Clinic Children’s.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.